Which has stronger valuation and earnings, AGEN or VOR?

Agenus has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 2.74 $120K $2.58 2.69 Vor Biopharma N/A N/A N/A N/A N/A

Is AGEN or VOR more profitable?

Agenus has a net margin of 69.33% compared to Vor Biopharma's net margin of 0.00%. Vor Biopharma's return on equity of 0.00% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Vor Biopharma N/A N/A N/A

Does the media favor AGEN or VOR?

In the previous week, Vor Biopharma had 4 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Vor Biopharma and 2 mentions for Agenus. Vor Biopharma's average media sentiment score of 0.53 beat Agenus' score of 0.28 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vor Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AGEN or MAZE more profitable?

Agenus has a net margin of 69.33% compared to Maze Therapeutics' net margin of 0.00%. Maze Therapeutics' return on equity of -34.94% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Maze Therapeutics N/A -34.94% -30.18%

Does the media favor AGEN or MAZE?

In the previous week, Maze Therapeutics had 7 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Maze Therapeutics and 2 mentions for Agenus. Maze Therapeutics' average media sentiment score of 0.45 beat Agenus' score of 0.28 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AGEN or AKTS?

Agenus has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 2.74 $120K $2.58 2.69 Aktis Oncology $6.50M 192.67 -$63.73M -$0.82 N/A

Is AGEN or AKTS more profitable?

Agenus has a net margin of 69.33% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Aktis Oncology N/A N/A N/A

Does the media prefer AGEN or AKTS?

In the previous week, Aktis Oncology had 1 more articles in the media than Agenus. MarketBeat recorded 3 mentions for Aktis Oncology and 2 mentions for Agenus. Aktis Oncology's average media sentiment score of 0.47 beat Agenus' score of 0.28 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AGEN or TRAX?

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Agenus. MarketBeat recorded 3 mentions for First Tracks Biotherapeutics and 2 mentions for Agenus. First Tracks Biotherapeutics' average media sentiment score of 0.86 beat Agenus' score of 0.28 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral First Tracks Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, AGEN or ALMS?

Agenus has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 2.74 $120K $2.58 2.69 Alumis $24.05M 49.40 -$243.32M -$3.86 N/A

Is AGEN or ALMS more profitable?

Agenus has a net margin of 69.33% compared to Alumis' net margin of -5,933.46%. Agenus' return on equity of -47.68% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Alumis -5,933.46% -93.15% -74.50%

Does the media favor AGEN or ALMS?

In the previous week, Alumis had 8 more articles in the media than Agenus. MarketBeat recorded 10 mentions for Alumis and 2 mentions for Agenus. Alumis' average media sentiment score of 0.69 beat Agenus' score of 0.28 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alumis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Agenus (AGEN) Competitors

$6.94 +0.05 (+0.73%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.90 -0.04 (-0.58%)

As of 09/11/2026 07:55 PM Eastern

Compare

AGEN vs. VOR, MAZE, AKTS, TRAX, and ALMS

Should you buy Agenus stock or one of its competitors? Agenus's main competitors and comparable companies include Vor Biopharma (VOR), Maze Therapeutics (MAZE), Aktis Oncology (AKTS), First Tracks Biotherapeutics (TRAX), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agenus compare to Vor Biopharma?

Agenus (NASDAQ:AGEN) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Agenus has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Agenus presently has a consensus price target of $19.50, suggesting a potential upside of 180.98%. Vor Biopharma has a consensus price target of $43.38, suggesting a potential upside of 94.51%. Given Agenus' higher probable upside, research analysts plainly believe Agenus is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Vor Biopharma had 4 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Vor Biopharma and 2 mentions for Agenus. Vor Biopharma's average media sentiment score of 0.53 beat Agenus' score of 0.28 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vor Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Vor Biopharma's net margin of 0.00%. Vor Biopharma's return on equity of 0.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Vor Biopharma	N/A	N/A	N/A

61.5% of Agenus shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 6.5% of Agenus shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vor Biopharma beats Agenus on 8 of the 13 factors compared between the two stocks.

How does Agenus compare to Maze Therapeutics?

Agenus (NASDAQ:AGEN) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Agenus has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A

Agenus presently has a consensus price target of $19.50, indicating a potential upside of 180.98%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 168.29%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Agenus has a net margin of 69.33% compared to Maze Therapeutics' net margin of 0.00%. Maze Therapeutics' return on equity of -34.94% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Maze Therapeutics	N/A	-34.94%	-30.18%

Agenus has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

61.5% of Agenus shares are held by institutional investors. 6.5% of Agenus shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Maze Therapeutics had 7 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Maze Therapeutics and 2 mentions for Agenus. Maze Therapeutics' average media sentiment score of 0.45 beat Agenus' score of 0.28 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maze Therapeutics beats Agenus on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Aktis Oncology?

Agenus (NASDAQ:AGEN) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

61.5% of Agenus shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Agenus currently has a consensus target price of $19.50, indicating a potential upside of 180.98%. Aktis Oncology has a consensus target price of $35.63, indicating a potential upside of 52.90%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Aktis Oncology had 1 more articles in the media than Agenus. MarketBeat recorded 3 mentions for Aktis Oncology and 2 mentions for Agenus. Aktis Oncology's average media sentiment score of 0.47 beat Agenus' score of 0.28 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
Aktis Oncology	$6.50M	192.67	-$63.73M	-$0.82	N/A

Agenus has a net margin of 69.33% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Aktis Oncology	N/A	N/A	N/A

Summary

Agenus beats Aktis Oncology on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to First Tracks Biotherapeutics?

Agenus (NASDAQ:AGEN) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Agenus presently has a consensus price target of $19.50, indicating a potential upside of 180.98%. First Tracks Biotherapeutics has a consensus price target of $63.00, indicating a potential upside of 72.89%. Given Agenus' higher possible upside, research analysts clearly believe Agenus is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Agenus. MarketBeat recorded 3 mentions for First Tracks Biotherapeutics and 2 mentions for Agenus. First Tracks Biotherapeutics' average media sentiment score of 0.86 beat Agenus' score of 0.28 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a net margin of 69.33% compared to First Tracks Biotherapeutics' net margin of 0.00%. First Tracks Biotherapeutics' return on equity of 0.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
First Tracks Biotherapeutics	N/A	N/A	N/A

Agenus has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

61.5% of Agenus shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Agenus beats First Tracks Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Agenus compare to Alumis?

Agenus (NASDAQ:AGEN) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

61.5% of Agenus shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alumis had 8 more articles in the media than Agenus. MarketBeat recorded 10 mentions for Alumis and 2 mentions for Agenus. Alumis' average media sentiment score of 0.69 beat Agenus' score of 0.28 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alumis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
Alumis	$24.05M	49.40	-$243.32M	-$3.86	N/A

Agenus presently has a consensus target price of $19.50, indicating a potential upside of 180.98%. Alumis has a consensus target price of $33.27, indicating a potential upside of 262.45%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Agenus has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Alumis has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

Agenus has a net margin of 69.33% compared to Alumis' net margin of -5,933.46%. Agenus' return on equity of -47.68% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Alumis	-5,933.46%	-93.15%	-74.50%

Summary

Agenus and Alumis tied by winning 8 of the 16 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$312.44M	$3.84B	$7.12B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	2.69	14.25	275.24	25.29
Price / Sales	2.74	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	-0.85	15.12	10.33	6.20
Net Income	$120K	-$22.86M	$3.50B	$358.50M
7 Day Performance	-15.78%	-4.34%	-3.32%	-2.35%
1 Month Performance	0.58%	-0.02%	-0.41%	-2.77%
1 Year Performance	54.91%	40.64%	19.21%	7.63%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	2.7925 of 5 stars	$6.94 +0.7%	$19.50 +181.0%	+46.4%	$312.44M	$114.20M	2.69	440
VOR Vor Biopharma	1.7374 of 5 stars	$25.05 flat	$43.38 +73.2%	-38.6%	$1.48B	N/A	N/A	140	Gap Up
MAZE Maze Therapeutics	2.4441 of 5 stars	$26.21 flat	$66.00 +151.8%	-0.8%	$1.46B	$167.50M	N/A	121	Insider Trade
AKTS Aktis Oncology	2.9128 of 5 stars	$27.05 flat	$35.00 +29.4%	N/A	$1.45B	$6.50M	N/A	76	Positive News Analyst Forecast Gap Down
TRAX First Tracks Biotherapeutics	2.6512 of 5 stars	$40.46 flat	$63.00 +55.7%	N/A	$1.45B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. VOR, MAZE, AKTS, TRAX, and ALMS

How does Agenus compare to Vor Biopharma?

Summary

How does Agenus compare to Maze Therapeutics?

Summary

How does Agenus compare to Aktis Oncology?

Summary

How does Agenus compare to First Tracks Biotherapeutics?

Summary

How does Agenus compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. VOR, MAZE, AKTS, TRAX, and ALMS

How does Agenus compare to Vor Biopharma?

Which has stronger valuation and earnings, AGEN or VOR?

Do analysts recommend AGEN or VOR?

Does the media favor AGEN or VOR?

Which has more volatility & risk, AGEN or VOR?

Is AGEN or VOR more profitable?

Do institutionals and insiders hold more shares of AGEN or VOR?

Summary

How does Agenus compare to Maze Therapeutics?

Which has stronger earnings & valuation, AGEN or MAZE?

Do analysts prefer AGEN or MAZE?

Is AGEN or MAZE more profitable?

Which has more volatility & risk, AGEN or MAZE?

Do institutionals & insiders believe in AGEN or MAZE?

Does the media favor AGEN or MAZE?

Summary

How does Agenus compare to Aktis Oncology?

Do institutionals and insiders believe in AGEN or AKTS?

Do analysts rate AGEN or AKTS?

Does the media prefer AGEN or AKTS?

Which has higher earnings and valuation, AGEN or AKTS?

Is AGEN or AKTS more profitable?

Summary

How does Agenus compare to First Tracks Biotherapeutics?

Do analysts recommend AGEN or TRAX?

Does the media refer more to AGEN or TRAX?

Is AGEN or TRAX more profitable?

Which has stronger earnings & valuation, AGEN or TRAX?

Do institutionals & insiders hold more shares of AGEN or TRAX?

Summary

How does Agenus compare to Alumis?

Do insiders & institutionals believe in AGEN or ALMS?

Does the media favor AGEN or ALMS?

Which has preferable earnings and valuation, AGEN or ALMS?

Do analysts recommend AGEN or ALMS?

Which has more risk & volatility, AGEN or ALMS?

Is AGEN or ALMS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools